ClinicalTrials.gg
RecruitingNCT07677332Updated Nov 18, 2026

Mandibular Advancement Device (MAD) and Continuous Positive Airway Pressure (CPAP) for Treatment of Adult Patients Diagnosed With Moderate Obstructive Sleep Apnea

An interventional study of Mandibular advancement device (MAD) and Continuous positive airway pressure (CPAP) in Obstructive Sleep Apnea (OSA), sponsored by University of Copenhagen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Copenhagen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 18, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Sleep Apnea, Obstructive with a site in Denmark — 6 open to participants now, 6 under way, 1 of them phase 3. Sleep Apnea, Obstructive · Denmark.

Planned enrollment
6th of 15
70 · median 51
Started
2026
with 2 others
No phase
10 of 26
3 open now
Registered
25th of 26
by date

Among the 26 studies in Sleep Apnea, Obstructive with a site in Denmark, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 with no phase, and was the 25th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

6 of the 26 studies in Sleep Apnea, Obstructive with a site in Denmark are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Sleep Apnea, Obstructive with a site in Denmark, or all of them as a file.
02

Study summary

Obstructive sleep apnea (OSA) is a frequent illness related to sleep and breathing with many symptoms and complications. The primary choices of treatment are continuous positive airway pressure (CPAP) and removable appliance for protruding the mandible when sleeping (MAD). Treatment with CPAP is superior to treatment with MAD but many patients don't tolerate CPAP why they seek treatment with MAD. In Denmark, treatment with MAD is not free of charge unlike treatment with CPAP and MAD is therefore not offered systematically to the patients. The same applies to adjustment, control and effect of the MAD treatment. MAD treatment has a positive effect on OSA in general but the effect varies due to differences in selection of patients and lack of specifying who performs and evaluates MAD treatment, the effect on sleep and possible side effects in muscles and the temporomandibular joint as well as the occlusion during treatment. It is therefore of great importance to investigate the effect of MAD treatment as well as short- and long-term side effects. The aim is therefore to compare the treatment effect of MAD and CPAP and how significant the investigation of the airways and the face is for the treatment effect and possible side effects. The project is a 4-year investigation and 70 adult patients diagnosed with moderate OSA are included. The results from the investigation will be of great importance for the choice of treatment and prognosis for the individual patient and socio-economic since the treatment of OSA could be tailored the individual patient and the treatment effect optimised.

03

Conditions studied

  • Obstructive Sleep Apnea (OSA)

Keywords

  • Obstructive sleep apnea
  • OSA
  • MAD
  • CPAP
  • Orthodontics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Objectively diagnosed with moderate OSA (AHI 15-29)
  • >/= 18 years
  • \</= 35 and neck circumference \<44cm
  • Fully sanitised at their own dentist (no periodontitis or caries requiring treatment. Periodontal bone loss \<50%)
  • >/= 20 teeth.
  • Evenly distributed occlusal contacts

Exclusion criteria

Exclusion Criteria:

  • Known craniofacial anomalies
  • General inflammatory joint diseases
  • Maximal protrusion of the mandible \< 6 mm
  • Severe deep bite
  • Anterior open bite
  • Severe attrition
  • Severe bruxism and involuntary mandibular movements
  • Conditions demanding treatment such as temporomandibular disorders (TMD)
  • Chronically pronounced nasal stenosis
  • Hypertrophic tonsils (tonsil size 3-4)
  • Prior blood clot in the brain or in the heart
  • Heart arrythmias
  • Other severe systemic diseases
  • Epilepsia
  • Allergies towards peanuts, soy or egg
  • Consumption of morphine or other sedatives which cannot be paused
  • Pregnant or breast-feeding women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    MAD-group

    Group starting with the MAD treatment

    Device: Mandibular advancement device (MAD) · Device: Continuous positive airway pressure (CPAP)

  • Experimental
    CPAP-group

    Group starting with the CPAP treatment

    Device: Mandibular advancement device (MAD) · Device: Continuous positive airway pressure (CPAP)

Interventions

  • DeviceMandibular advancement device (MAD)

    18 months of treatment with MAD in total.

  • DeviceContinuous positive airway pressure (CPAP)

    6 months of treatment with CPAP in total.

06

What researchers measure

Primary outcomes

  1. Objective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by Apnea-Hypopnea Index (AHI)

    Defined as the number of apneas and hypopneas per hour of sleep, with higher values indicating greater severity

    Time frame: From enrollment to the end of treatment at 24 months

  2. Objective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by Oxygen Desaturation Index (ODI)

    Defined as the number of oxygen desaturation events per hour of sleep, with higher values indicating more severe nocturnal hypoxemia

    Time frame: From enrollment to the end of treatment at 24 months

  3. Objective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by acoustic pharyngo- and rhinometry

    Measured as volume, mean area, minimum cross-sectional area (MCA), distance to MCA and calculated resistance

    Time frame: From enrollment to the end of treatment at 24 months

  4. Subjective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by Epworth Sleepiness Scale (ESS)

    Scale 0-24, higher scores indicate greater daytime sleepiness

    Time frame: From enrollment to the end of treatment at 24 months

  5. Subjective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by Pittsburgh Sleep Quality Index (PSQI)

    Scale 0-21, higher scores indicate worse sleep quality

    Time frame: From enrollment to the end of treatment at 24 months

  6. Subjective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by Berlin Questionnaire (BQ)

    The Berlin Questionnaire classifies individuals as high or low risk for obstructive sleep apnea based on three symptom categories; high risk is defined as having two or more positive categories

    Time frame: From enrollment to the end of treatment at 24 months

  7. Subjective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by Short Form 36 (SF-36)

    The SF-36 assesses health-related quality of life across eight domains, each scored from 0 to 100, with higher scores indicating better health status

    Time frame: From enrollment to the end of treatment at 24 months

Secondary outcomes

  1. The significance of DISE and craniofacial morphology for the objective and subjective treatment effect of MAD and CPAP assessed by lateral cephalogram

    Measured with standardized cephalometric angular measurements

    Time frame: At baseline and at the end of treatment at 24 months

  2. The significance of DISE and craniofacial morphology for the objective and subjective treatment effect of MAD and CPAP assessed by cone-beam CT (CBCT)

    Assessment of upper airway dimensions

    Time frame: At baseline and at the end of treatment at 24 months

  3. The significance of DISE and craniofacial morphology for the objective and subjective treatment effect of MAD and CPAP assessed by VOTE-classification

    The VOTE classification evaluates obstruction at four anatomical levels (velum, oropharynx, tongue base, epiglottis), with each site scored according to the degree of collapse (0-2), where higher scores indicate greater obstruction

    Time frame: DISE is performed before treatment

  4. The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by VOTE-classification

    The VOTE classification evaluates obstruction at four anatomical levels (velum, oropharynx, tongue base, epiglottis), with each site scored according to the degree of collapse (0-2), where higher scores indicate greater obstruction

    Time frame: DISE is performed before treatment.

  5. The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by lateral cephalogram

    Measured with standardized cephalometric angular measurements

    Time frame: At baseline and at the end of treatment at 24 months

  6. The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by cone-beam CT (CBCT)

    Assessment of upper airway dimensions

    Time frame: At baseline and at the end of treatment at 24 months

  7. The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by Diagnostic Criteria for Temporomandibular Disorders (DC/TMD)

    The DC/TMD is applied using both patient-reported symptom questionnaires and a structured clinical examination

    Time frame: From enrollment to the end of treatment at 24 months

  8. The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by dental occlusion

    Dental occlusion assessed by intraoral scans and number of dental contacts in intercuspidal position (ICP)

    Time frame: From enrollment to the end of treatment at 24 months

  9. The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by bite-force

    Measured in newtons (N)

    Time frame: From enrollment to the end of treatment at 24 months

  10. The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by short-form Oral Health Impact Profile (OHIP-14)

    The OHIP-14 assesses oral health-related quality of life across seven domains, with each item scored from 0 (never) to 4 (very often), yielding a total score ranging from 0 to 56, where higher scores reflect greater impairment

    Time frame: From enrollment to the end of treatment at 24 months

  11. The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by Nordic Oro-facial Test-Screening (NOT-S)

    The NOT-S consists of 12 domains (6 interview-based and 6 examination-based), each scored as 0 or 1, yielding a total score from 0 to 12, with higher scores indicating more severe orofacial dysfunction

    Time frame: From enrollment to the end of treatment at 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2029, 29 months after the start.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 29 months is below that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 30, 2026
StartActual
Oct 7, 2026was Aug 2026
Primary completionEst.
Mar 2029
CompletionEst.
Aug 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
University of Copenhagen is now Recruiting
Nov 18, 2026
Start date
Aug 2026→Oct 7, 2026 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    University of Copenhagen is now Recruiting
    Start date Aug 2026→Oct 7, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07677332
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Oct 7, 2026
Primary completion
Mar 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Clara Hartogsohn, PhD Student
Contact
clara.hartogsohn@sund.ku.dk
+4535321136
Liselotte Sonnesen, Professor
Contact
alson@sund.ku.dk
+4535326670
Liselotte Sonnesen, Professor
principal investigator · University of Copenhagen

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion